Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells

Journal of Pathology

Volumn 222, Issue 3, 2010, Pages 249-260

  Zhuo, Wei ^a   Luo, Chong ^a   Wang, Xiaofeng ^a   Song, Xiaomin ^a   Fu, Yan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Endostatin; Endothelial cell; Lymph node; Lymphangiogenesis; Nucleolin; Tumour metastasis

Indexed keywords

ENDOSTATIN; NUCLEOLIN; SMALL INTERFERING RNA; PHOSPHOPROTEIN; RECOMBINANT PROTEIN; RNA BINDING PROTEIN;

ARTICLE; CELL MIGRATION; CELL SURFACE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; LYMPH VESSEL; LYMPHATIC METASTASIS; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ENDOSTATINS; ENDOTHELIAL CELLS; FEMALE; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHOPROTEINS; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958003713     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2760     Document Type: Article

References (46)

1. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
2. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999;18:4414-4423.
3. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-407.
4. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-3803.
5. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-663.
6. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001;98:1024-1029.
7. MacDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-25196.
8. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-822.
9. Sasaki T, Fukai N, Mann K, et al. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998;17:4249-4256.
10. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-5413.
11. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007;110:2899-2906.
12. Huang Y, Shi H, Zhou H, et al. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006;107:3564-3571.
13. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999;13:1911-1922.
14. Borer RA, Lehner CF, Eppenberger HM, et al. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989;56:379-390.
15. Christian S, Pilch J, Akerman ME, et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003;163:871-878.
16. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001;50:3-20.
17. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005;115:247-257.
18. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nature Rev Cancer 2005;5:735-743.
19. Gao P, Zhou GY, Zhang QH, et al. Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol 2009;218:192-200.
20. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002;82:673-700.
21. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290-298.
22. Royston D, Jackson DG. Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 2009;217:608-619.
23. Kajiya K, Hirakawa S, Ma B, et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005;24:2885-2895.
24. Tammela T, Saaristo A, Lohela M, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005;105:4642-4648.
25. Bjorndahl M, Cao R, Nissen LJ, et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A 2005;102:15593- 15598.
26. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.
27. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6:333-345.
28. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nature Med 2009;15:1023-1030.
29. Fukumoto S, Morifuji M, Katakura Y, et al. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 2005;22:31-38.
30. Brideau G, Makinen MJ, Elamaa H, et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007;67:11528-11535.
31. Mancardi S, Stanta G, Dusetti N, et al. Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant. Exp Cell Res 1999;246:368-375.
32. Garmy-Susini B, Makale M, Fuster M, et al. Methods to study lymphatic vessel integrins. Methods Enzymol 2007;426:415-438.
33. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 1991;88:5026-5030.
34. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003;162:575-586.
35. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-27879.
36. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006;94:1355-1360.
37. Tobler NE, Detmar M. Tumor and lymph node lymphangiogenesis-impact on cancer metastasis. J Leukoc Biol 2006;80:691-696.
38. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005;7:121-127.
39. Dietrich T, Onderka J, Bock F, et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol 2007;171:361-372.
40. Okazaki T, Ni A, Ayeni OA, et al. Alpha5beta1 integrin blockade inhibits lymphangiogenesis in airway inflammation. Am J Pathol 2009;174:2378-2387.
41. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med 2001;7:192-198.
42. Wong SY, Haack H, Crowley D, et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005;65:9789-9798.
43. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 2003;200:195-206.
44. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315-1320.
45. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008;216:347-354.
46. Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089-1099.